Notice type: 3rd Party Publications
Problem Or Issue:
Important Safety Information from Novartis Gene Therapies EU on risk for thrombotic microangiopathy of Zolgensma (onasemnogene abeparvovec)
Important Safety Information - Zolgensma (onasemnogene abeparvovec)